The Almond Yogurt Study (AYS) (AYS)
The Impact of Almond Food Structure in a Standardized Yogurt Breakfast Meal on Gastric Emptying, Oral Processing Behaviours, Appetite-Regulating Hormones, Postprandial Metabolism, and Subjective Satiety: A Randomized Crossover Trial
The goal of this clinical trial is to explore how almond food structure influences gastric emptying rates when consumed by healthy adult women as part of a standardized breakfast meal. The main questions it aims to answer are:
- Does the structure of almonds (whole, chopped, buttered) influence gastric emptying ?
- What is the correlation between chewing behaviour, gastric emptying, and changes in postprandial triacylglycerols and satiety (hormones and ratings) within the context of an increasingly disrupted nut matrix.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study is investigating how the structure of almonds (whole, chopped, buttered) as part of a yogurt-based breakfast meal influences gastric emptying and postprandial metabolism. Over three randomized visits, fasted healthy adult female participants will arrive at the research centre where an iv-catheter will be inserted for serial blood sampling over 6 hours for analysis of plasma triacylglycerols, GLP-1, CCK, glucose, and insulin. Participants will consume each meal while being video recorded to quantify chewing frequency and eating time. Paper questionnaires will periodically assess participants' eating experiences and hunger sensations throughout the visit (e.g., exertion, liking, hunger, fullness). Gastric ultrasonography will be used to visualize and quantify the cross-sectional area of the gastric antrum so that changes in gastric volume can be tracked over time. Overall, this study aims to determine how almond form, as an example of food structure, influences chewing, gastric emptying, satiety and postprandial metabolism.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Amanda J Wright, PhD
- Phone Number: 54697 519-824-4120
- Email: ajwright@uoguelph.ca
Study Locations
-
-
Ontario
-
Guelph, Ontario, Canada, N1G 2G4
- Department of Human Health Sciences
-
Contact:
- Amanda J Wright, PhD
- Phone Number: 54697 5190824-4120
- Email: ajwright@uoguelph.ca
-
Contact:
- Alison M Duncan, PhD
-
Principal Investigator:
- Amanda J Wright, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy female adults aged 18-45 years.
- Body Mass Index (BMI) between 18.5-27.9 kg/m2, or waist circumference of less than 88 cm
- Visible gastric antrum on ultrasound
- No known food allergies or sensitivities
- Non restrained eaters (TFEQ, see below)
- No history of gastrointestinal diseases that may interfere with eating behavior or digestion
- Not on medications that affect appetite (including GLP-1 agonists), digestion, blood sugar regulation, saliva production, or chewing
- Stable medication use
- Non-smokers
- Not gained or lost significant weight during the past 3 months
- Regular monthly menstrual cycles
- Not pregnant, lactating or post-menopausal
Exclusion Criteria:
- Diabetes or other metabolic disorders affecting glycemia and overall cardiometabolic health
- Blood pressure > 140/90 mm Hg
- Any food allergies, intolerances, or sensitivities
- Pregnant or breastfeeding
- Participation in another clinical trial
- Excessive alcohol consumption (more than 14 drinks per week)
- Smokers or those with a smoking history of more than 10 years
- Regular use of recreational drugs (e.g., marijuana, ecstasy, LSD, magic mushrooms, etc.)
- Restrained eater (>16) as defined by the questionnaire at screening (Three-Factor Eating Questionnaire, Stunkard et al., 1985)
- Unusual sleep patterns
- Irregular breakfast consumption
- Recent weight changes, or intended weight loss or gain; lost/gained 10% of body weight within the last 6 months
- Food allergies/sensitivities or any life-threatening allergies
- Using medications known to affect appetite, digestion, blood sugar regulation, or chewing/swallowing (excluding oral contraceptives).
- Experiences dry mouth in general or due to medication side effects
- Inability to adhere to study protocols
- Not comfortable providing IV-line blood samples
- Not comfortable providing ultrasound scans
- Not comfortable being video recorded while eating
- Avoids consuming almonds/yogurt in general
- Avoids eating hard foods to prevent dental fractures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Whole - Chopped - Buttered
Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, chopped almonds at the second intervention visit, and almonds processed into almond butter at the third intervention visit. |
Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms. |
|
Experimental: Whole - Buttered - Chopped
Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, buttered almonds at the second intervention visit, and chopped almonds at the third intervention visit. |
Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms. |
|
Experimental: Buttered - Whole - Chopped
Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, whole almonds at the second intervention visit, and chopped almonds at the third intervention visit. |
Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms. |
|
Experimental: Buttered - Chopped - Whole
Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, chopped almonds at the second intervention visit, and whole almonds at the third intervention visit. |
Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms. |
|
Experimental: Chopped - Buttered - Whole
Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, buttered almonds at the second intervention visit, and whole almonds at the third intervention visit. |
Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms. |
|
Experimental: Chopped - Whole - Buttered
Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, whole almonds at the second intervention visit, and buttered almonds at the third intervention visit. |
Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gastric emptying half-time
Time Frame: At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Calculated from ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after consumption of the breakfast meal, in minutes |
At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Eating time
Time Frame: From 0 minutes until the end of eating the breakfast meal
|
The time to consume the breakfast meal based on video recordings, in minutes |
From 0 minutes until the end of eating the breakfast meal
|
|
Changes from baseline in postprandial satiety visual analogue scale ratings
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Paper questionnaire scale ratings (in mm) of Hunger, Fullness, Prospective Consumption, and Desire to Eat where each is 100 mm ranging from 0 (minimum) to 100 (maximum). For example, 0 = Not at all Hungry and 100 = As Hungry as Possible. |
0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Changes from baseline in plasma triacylglycerol concentration
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Based on analysis of serial blood draws, in mmol/L |
0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Triacylglycerol response - incremental area under the curve (AUC)
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Calculated based on baseline and postprandial plasma concentrations |
0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Changes from baseline in plasma GLP-1 concentration
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Based on analysis of serial blood draws, in pg/mL |
0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
GLP-1 response - incremental area under the curve (AUC)
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Calculated based on baseline and postprandial plasma concentrations |
0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Changes from baseline in plasma CCK concentration
Time Frame: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Based on analysis of serial blood draws, in pmol/L |
0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
CCK response - incremental area under the curve (AUC)
Time Frame: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Calculated based on baseline and postprandial plasma concentrations |
0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Changes from baseline in gastric volume
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Calculated based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal, in mL |
0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Gastric volume - incremental area under the curve (AUC)
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal |
0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Borg rating of perceived exertion
Time Frame: Immediately after the breakfast meal is consumed
|
Participant paper scale rating of effort required to chew the breakfast meal where 0 = No effort at all and 10 = Very very severe chewing effort |
Immediately after the breakfast meal is consumed
|
|
Changes from baseline in plasma blood glucose concentration
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Based on analysis of serial blood draws, in mmol/mL |
0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Glucose response - incremental area under the curve (AUC)
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Calculated based on baseline and postprandial plasma concentrations |
0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Changes from baseline in plasma blood insulin concentration
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Based on analysis of serial blood draws, in pmol/mL |
0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Insulin response - Area under the curve (AUC)
Time Frame: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
Calculated based on baseline and postprandial plasma concentrations |
0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
|
|
Product liking and perceived attributes
Time Frame: Immediately after eating the breakfast meal
|
Participant paper scale questionnaire ratings |
Immediately after eating the breakfast meal
|
|
Eating rate
Time Frame: From 0 minutes until the end of eating the breakfast meal
|
Calculated from video recordings of eating session, combining meal portion consumed (in grams) and eating time (minutes), grams/minute |
From 0 minutes until the end of eating the breakfast meal
|
|
Number of chews
Time Frame: From 0 minutes until the end of eating the breakfast meal
|
Determined by count from video recordings of each eating session |
From 0 minutes until the end of eating the breakfast meal
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ID3014
- 400819 (Other Grant/Funding Number: Natural Sciences & Engineering Research Council of Canada)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Although we are not required to make this data available, we are currently working to understand how to do this in a safe way, as per our institutional guidelines. As we learn more, we may pursue this. We are obtaining consent from study participants for this option.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.